HAYA Therapeutics’ Post

Dear all! Join Proteintech´s next Webinar: "Visualization of m6A residues in individual mRNAs". When: May 30th, 2024 | 2pm US CT | 2pm BST | 3pm CEST Event info: Join Charles Sheehan, a PhD candidate from Duke University Medical Center, as he presents groundbreaking research on DART-FISH,offering unparalleled insights into mRNA methylation dynamics. N6-methyladenosine (m6A) is an abundant RNA base modification and is critical for regulating gene expression. While traditional sequencing-based approaches have enabled invaluable insights into m6A function, methods for visualizing m6A-modified mRNAs in cells are currently lacking. In this webinar, Charles Sheehan will share his work on a novel method that enables the simultaneous visualization of methylated and unmethylated mRNA molecules in cells. That has the potential for unprecedented insights into the regulation of methylated transcripts in health and disease. The workshop will include: ·        Detailed Q&A with the speaker ·        Free product sample ·        A certificate of attendance and a link to watch the webinar will be available to attendees post-event. Register here: https://lnkd.in/dmuPX9n4 See you there!

The future of circRNAs in both research and clinical applications is highly promising. Their unique properties present exciting opportunities for novel therapeutic strategies and diagnostic tools. Continued advancements in circRNA research and technology have the potential to lead to groundbreaking innovations in disease treatment and a deeper understanding of gene regulation. One of the critical aspects of circular RNA production is its design, the excellent design strategy of circular RNA determines the circularization rate and the stability of circular RNA. In sequence design, YXgene possesses exceptional capabilities in circularization strategies for circRNAs, the design of translational elements such as IRES, and the engineering of secondary structures. #circRNA #mRNAtechnology #mRNA #biotechnology #clinicalresearch

Have you ever wondered how something so small can have such a massive impact on human life?   MicroRNAs (miRNAs), small components made of just 21-23 nucleotides, are non-coding RNA sequences that play a crucial role in regulating gene expression. Their discovery by Victor Ambros and Gary Ruvkun, recognized with a 2024 Nobel Prize in Physiology or Medicine.   Since this groundbreaking finding, miRNAs have transformed medical research. Today, there are over 1,300 clinical trials registered on ClinicalTrials.gov investigating their therapeutic potential in wide range of indications 🧬   As we continue to explore the world of gene regulation, miRNAs are proving to be a powerful tool in unlocking new avenues of precision medicine. This is an exciting time to be involved in clinical trials and the future of healthcare!   And if you need support in the path of clinical trials - KCRI comes to your aid.   #GeneRegulation #MicroRNA #ClinicalResearch #PrecisionMedicine #ClinicalTrials #HealthcareInnovation

Don't miss our poster presentations at Discovery on Target in Boston, MA! 📃 "Identification and characterization of small molecules inhibiting RNA targets: miRNA" 🏷 Session A, poster A39 📆 October 1st to 2nd a.m. 👩🏼🔬 Paola C., PhD, Director Alliance Management Abstract: RNA plays a key role in transcription and translation: gene regulation, proliferation, apoptosis, and development. The biological function is linked to the unique secondary and tertiary structures. Many diseases are associated with dysregulation of RNA functions, so there is a growing interest in RNAs as drug targets for novel therapies or targeting undruggable proteins. The most used modalities are antisense oligonucleotides (ASOs), CRISPR gene editing, and more recently small molecules. [...] Discover more about our approach that demonstrates a miRNA targeting platform that could be applied to other oncogenic miRNA targets: https://lnkd.in/edM4ecJj For more questions and details, come and meet our team at our booth 508! #DrugDiscovery #Biophysics #RNA #SPR #microRNA #DiscoveryOnTarget #BostonDOT24

In case you missed it, our free webinar - HTS in Search of RNA Splicing Modulators Using a HiBiT Assay, which we are bringing to you in collaboration with Axxam is now available on demand at https://bit.ly/3Wgv1lv Cytoplasmic aggregation of mis-localised proteins is a common pathological hallmark in neurodegenerative disorders. Dysregulation of nuclear DNA binding proteins crucial for RNA stabilisation, transcription, and splicing leads to aberrant gene expression, resulting in the accumulation of truncated variants. Recent findings directly associate these variants with severe neurological conditions. We developed a bioluminescent cell-based assay capable of mimicking this pathology through inducible protein depletion, utilising HiBiT tagging of the gene of interest (GOI). Our fast, sensitive and simple assay enables high-throughput screening for RNA splicing modulators, offering a potential avenue to restore proper expression of the wild-type GOI isoform, and therefore of the wild-type protein. In this webinar, learn about: o HiBiT protein tagging technology from Promega and its applications in drug discovery o The development of a bioluminescent cell-based assay using HiBiT technology for screening for RNA splicing modulators o Axxam’s HTS campaign in search of RNA splicing modulators #HiBiT #DNABinding #RNA

🧬  NTx Spotlight at ASGCT 2024: Advancing Genetic Medicines 🧬   Jessica Silva, a dedicated scientist at NanoVation Therapeutics, is gearing up to present our latest research at the American Society of Gene & Cell Therapy Annual Meeting. She will be diving into our sophisticated use of Long-Circulating Lipid Nanoparticles (LCLNP) for targeted delivery of nucleic acids — a key innovation in our genetic medicine toolbox.   📅 Date & Time: May 9, 2024, at 12:00 PM ET 🔍 Abstract #0032  🔬 Title: "Long-Circulating Lipid Nanoparticles (LCLNP) Effectively Deliver Nucleic Acids to Hematopoietic Stem and Progenitor Cells in the Bone Marrow"   This presentation will explore the forefront of LCLNP technology and its potential to transform genetic medicine. Jess’s insights are paving the way for innovative treatments targeting bone marrow cells, crucial in combating various diseases.   Don't miss the chance to see how NTx is shaping the landscape of advanced therapeutics.   #ASGCT2024  #InnovativeResearch #Biotech #genetherapy #RNA #Nucleicacid

If you're attending #ASGCT this week, make sure to catch the oral and poster presentations featuring contributions from my colleagues at BlueRock Therapeutics. I'll be there too, eager to explore the latest technologies in cell and gene therapy. Look forward to learning from all the brilliant minds and cutting-edge research at #ASGCT2024. Safety, Tolerability, and Clinical Assessment of #Bemdaneprocel for Parkinson’s Disease: Results up to 18 Months from a Phase 1 Study Type: Oral Abstract Session Session Title: Cell Therapy and Cell-Based Gene Therapy Trials https://lnkd.in/e6uR2rt4 Engineered IMiD Regulated Synthetic Transcriptional Switch for Controlled and Dose-Responsive Expression of Therapeutic Payload within FDA-Approved Drug Doses Type: Poster Session Thursday Poster Board Number: 1285 https://lnkd.in/eSFJqcYz Iterative Engineering of Polarization-State Responsive Synthetic Promoters for Autonomous Control of Macrophage Polarization Logic Type: Poster Session Friday Poster Board Number: 1799 https://lnkd.in/eXRQGDYg

Discover HER2-postive CTCs predictive value. https://lnkd.in/eeXbdgVk Patients with HER2-negative primary tumours, but HER2-positive CTCs, who received lapatinib in the DETECT III trial, showed improved overall survival compared with those who did not receive the targeted therapy. Harness the potential of ANGLE’s advanced HER2 testing service to enhance longitudinal monitoring, predict therapeutic responses, and optimise subject selection in clinical research. Our innovative approach combines immunofluorescence (IF) staining and fluorescence in situ hybridisation (FISH), to identify and quantify HER2 protein expression and gene amplification in circulating tumour cells (CTCs). For Research Use Only. Not for Use In Diagnostic Procedures. #CancerResearch #HER2 #CirculatingTumourCells

The article titled explores how endocrine-disrupting chemicals (EDCs) like Bisphenol S (BPS) can cause epigenetic mutations (epimutations) that may be passed down to future generations. BPS induced unique epimutations in each cell type, with differences in both quality and quantity. These epimutations were prevalent in regions associated with estrogen-response elements (EREs). The study found a relationship between the presence of estrogen receptor gene expression and the number of DNA methylation and gene expression changes.

Discover the predictive value of HER2-positive CTCs! 🧬 The DETECT III trial shows improved survival in patients with HER2-positive CTCs treated with lapatinib. ANGLE’s advanced HER2 testing service offers precise longitudinal monitoring and optimized subject selection for research. For Research Use Only. Not for Use In Diagnostic Procedures.